Ftse Mib
34.834,30
0,95%
DAX
18.652,67
0,44%
S&P 500
5.352,96
-0,02%
NASDAQ
17.173,12
-0,09%
Bitcoin
70.888,54
0,18%
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ImmunityBio Inc (IBRX) ImmunityBio Inc (IBRX) Notizie

IBRX

ImmunityBio (IBRX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IBRX
DataOraFonteTitoloSimboloCompagnia
17/05/202415:00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
09/05/202423:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
07/05/202414:00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
02/05/202422:04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202414:00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202406:03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
23/04/202403:56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
06/03/202415:00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
05/03/202415:00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
26/02/202422:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
24/02/202403:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
21/02/202415:00Business WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
05/02/202415:00Business WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
04/01/202403:59Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
02/01/202412:00Business WireImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionNASDAQ:IBRXImmunityBio Inc
16/11/202315:00Business WireImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
07/11/202315:00Business WireFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityNASDAQ:IBRXImmunityBio Inc
26/10/202318:03Dow Jones NewsImmunityBio Shares Rally as FDA Accepts N-803 ResubmissionNASDAQ:IBRXImmunityBio Inc
26/10/202315:00Business WireFDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA DateNASDAQ:IBRXImmunityBio Inc
23/10/202317:00Dow Jones NewsImmunityBio Shares 11% Higher on License Application Resubmission for N-803NASDAQ:IBRXImmunityBio Inc
23/10/202315:00Business WireImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituNASDAQ:IBRXImmunityBio Inc
28/09/202312:06Edgar (US Regulatory)Form DEF 14C - Other definitive information statementsNASDAQ:IBRXImmunityBio Inc
22/09/202321:06Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:IBRXImmunityBio Inc
11/09/202312:00Business WireImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant EntitiesNASDAQ:IBRXImmunityBio Inc
29/08/202311:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)NASDAQ:IBRXImmunityBio Inc
11/08/202311:45PR Newswire (US)IBRX SHAREHOLDER ALERT: Jakubowitz Law Reminds ImmunityBio Shareholders of a Lead Plaintiff Deadline of August 29, 2023NASDAQ:IBRXImmunityBio Inc
03/08/202315:00Business WireImmunityBio Names Enrique Diloné as Chief Technology OfficerNASDAQ:IBRXImmunityBio Inc
25/07/202323:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IBRXImmunityBio Inc
21/07/202302:32Business WireImmunityBio Announces Execution of $40 Million Equity Financing with Institutional InvestorsNASDAQ:IBRXImmunityBio Inc
10/07/202315:30Business WirePhase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer PatientsNASDAQ:IBRXImmunityBio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:IBRX

La tua Cronologia

NASDAQ
ABAKGXX
Hsbc Bank Usa Na Capped ...
NASDAQI
YLDATR
ISE High Income TR
BIT
UB4Q6L
Unicredit Bank
EU
B266
L etat Belge Belgische S...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network